Immune Design Corp. Company Profile (NASDAQ:IMDZ)

Analyst Ratings

Consensus Ratings for Immune Design Corp. (NASDAQ:IMDZ) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $30.00 (318.99% upside)

Analysts' Ratings History for Immune Design Corp. (NASDAQ:IMDZ)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2016Jefferies GroupReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Immune Design Corp. (NASDAQ:IMDZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/10/2016Q1($0.62)($0.61)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4($0.54)($0.60)$1.06 million$1.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.39)($0.37)$4.10 million$4.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.47)($0.54)$1.71 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.64)($0.56)$1.30 million$1.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/31/2015($0.68)($0.78)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q3 14($0.36)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Immune Design Corp. (NASDAQ:IMDZ)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.56)($0.56)($0.56)
Q2 20162($0.75)($0.63)($0.69)
Q3 20162($0.83)($0.61)($0.72)
Q4 20162($0.76)($0.65)($0.71)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immune Design Corp. (NASDAQ:IMDZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Immune Design Corp. (NASDAQ:IMDZ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/15/2016Stephen R BradyEVPBuy1,500$6.84$10,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/23/2015Wayne GombotzinsiderSell5,000$20.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Wayne GombotzinsiderSell5,000$16.19$80,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2015Lewis W ColemanDirectorBuy3,000$14.50$43,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2015Proquest Investments Iv, L.P.Major ShareholderSell177,607$21.60$3,836,311.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2015Proquest Investments Iv, L.P.Major ShareholderSell82,892$26.81$2,222,334.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2015Franklin M BergerDirectorBuy25,000$26.50$662,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2015Proquest Investments Iv, L.P.Major ShareholderSell45,820$26.51$1,214,688.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2015Proquest Investments Iv, L.P.Major ShareholderSell53,914$28.23$1,521,992.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2015Proquest Investments Iv, L.P.Major ShareholderSell7,495$26.72$200,266.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2015Proquest Investments Iv, L.P.Major ShareholderSell18,156$27.64$501,831.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Proquest Investments Iv, L.P.Major ShareholderSell44,464$27.52$1,223,649.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2015Proquest Investments Iv, L.P.Major ShareholderSell50,309$26.09$1,312,561.81View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2015Proquest Investments Iv, L.P.Major ShareholderSell129,342$24.94$3,225,789.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Proquest Investments Iv, L.P.Major ShareholderSell39,446$25.45$1,003,900.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/29/2014Alta Partners Viii, L.P.Major ShareholderBuy299,559$12.00$3,594,708.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/29/2014Franklin M BergerDirectorBuy50,000$12.00$600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Immune Design Corp. (NASDAQ:IMDZ)
DateHeadline
07/21/16 01:08 PMETF’s with exposure to Immune Design Corp. : July 21, 2016 -
07/14/16 08:07 AMNew Market Lows Stock Leaders – AVGR, CLDC, IMDZ, RGNX, IMGN, CVI, XPLR
07/01/16 04:13 PMIMMUNE DESIGN CORP. Files SEC form 8-K, Change in Directors or Principal Officers -
06/16/16 07:39 AMImmune Design Appoints Susan L. Kelley, M.D. to Board of Directors - [at noodls] - SEATTLE and SOUTH SAN FRANCISCO, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Susan ...
06/08/16 04:54 PMAnalysts Forecast 33% Upside For IBB
06/08/16 07:08 AMImmune Design Releases New PFS, OS and TME Data from Trials of Three Immuno-Oncology Product Candidates - [at noodls] - SEATTLE and SOUTH SAN FRANCISCO, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced updated results from ...
06/01/16 07:00 AMImmune Design Announces Upcoming Events - [GlobeNewswire] - -Jefferies 2016 Healthcare Conference Presentation-- Company Update Webcast June 8 in New York-. SEATTLE and SOUTH SAN FRANCISCO, Calif., June 01, 2016-- Immune Design, a clinical-stage immunotherapy company ...
05/06/16 06:16 PMImmune Design (IMDZ) Q1 Earnings: What Awaits the Stock? - Immune Design Corp. IMDZ is scheduled to report first-quarter 2016 results after the market closes on May 10. The company has a mixed track record so far. It beat estimates in two of the last four trailing quarters and missed the same on two other ...
03/15/16 05:09 AMIMMUNE DESIGN CORP. Files SEC form 10-K, Annual Report -
03/11/16 08:30 AMImmune Design Loss Wider than Expected, Pipeline in Focus -
03/10/16 03:29 PMImmune Design reports 4Q loss -
03/10/16 03:23 PMIMMUNE DESIGN CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib -
03/10/16 03:01 PMImmune Design Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update - [GlobeNewswire] - SEATTLE and SOUTH SAN FRANCISCO, Calif., March 10, 2016-- Immune Design, a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the fourth ...
03/10/16 06:07 AMQ4 2015 Immune Design Corp Earnings Release - After Market Close -
03/08/16 09:10 AMWhat Awaits Immune Design (IMDZ) this Earnings Season? -
03/04/16 07:00 AMImmune Design’s GLAAS™ Platform Shown to Modulate the Allergic Immune Response - [GlobeNewswire] - Establishes Potential for the Treatment of Pollen and Peanut Allergies. Data Presented at American Academy of Allergy, Asthma& Immunology Annual Meeting. SEATTLE and SOUTH SAN FRANCISCO, March 04, 2016-- ...
03/03/16 07:00 AMImmune Design to Report Fourth Quarter and Year End 2015 Financial Results - [GlobeNewswire] - SEATTLE and SOUTH SAN FRANCISCO, March 03, 2016-- Immune Design, a clinical-stage immunotherapy company focused on cancer, today announced that it will report fourth quarter and year end 2015 financial ...
02/29/16 07:00 AMImmune Design to Present at Cowen and Company 36th Annual Health Care Conference - [GlobeNewswire] - SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 29, 2016-- Immune Design, a clinical-stage immunotherapy company focused on oncology, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive ...
02/26/16 09:24 AMImmune Design Corp (IMDZ) is Trading Higher on Unusual Volume for February 24 - Equities.com - Immune Design Corp (IMDZ) is Trading Higher on Unusual Volume for February 24Equities.comImmune Design Corp (IMDZ) experienced unusually high volume on Feb. 24, as the stock gained 7.11% to a closing price of $10.10. The stock saw 164,589 shares trade hands over the course of the day on 859 trades. Given that the stock's average daily ...
02/20/16 01:55 PMDoes Immune Design Corp Have Any Gas After Today's Huge Decline? - Franklin Independent - Does Immune Design Corp Have Any Gas After Today's Huge Decline?Franklin IndependentThe stock of Immune Design Corp (NASDAQ:IMDZ) is a huge mover today! The stock decreased 5.53% or $0.65 during the last trading session, hitting $11.11. About 83,649 shares traded hands. Immune Design Corp (NASDAQ:IMDZ) has declined 53.72% ...
02/16/16 03:40 PMIMMUNE DESIGN CORP. Files SEC form 8-K/A, Financial Statements and Exhibits -
02/09/16 12:31 PMImmune Design (IMDZ) Issues Positive Update from Ongoing CMB305 and G100 Phase 1s - Immune Design (Nasdaq: IMDZ) reported positive topline data from three ongoing ... If afforded the opportunity to present, it is the company’s intent to work with the Principal Investigator for each product candidate to present a more complete data ...
02/09/16 07:03 AM8:03 am Immune Design reports 'Positive' Topline Data From Three Phase 1 Clinical Trials of Immuno-oncology Product Candidates -
02/09/16 07:00 AMImmune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-oncology Product Candidates - [GlobeNewswire] - SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 09, 2016-- Immune Design, a clinical-stage immunotherapy company focused on oncology, today reported positive topline data from three ongoing Phase 1 oncology ...
02/04/16 07:00 AMImmune Design to Present at Leerink Partners 5th Annual Global Healthcare Conference - [GlobeNewswire] - SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 04, 2016-- Immune Design, a clinical-stage immunotherapy company focused on oncology, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive ...
02/03/16 11:42 AMImmune Design is Now Oversold (IMDZ) - A stock is considered to be oversold if the RSI reading falls below 30. In trading on Wednesday, shares of Immune Design Corp (IMDZ) entered into oversold territory, hitting an RSI reading of 28.9, after changing hands as low as $9.69 per share.
02/01/16 06:02 PMGenocea Doses Patients in Phase IIb Study on GEN-003 -
02/01/16 09:10 AMImmunoGen Posts Wider-than-Expected Loss, Retains View -
01/29/16 11:40 AMImmune Design Corp. (IMDZ) - 12-Nov-15 IMMUNE DESIGN CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib 3-Nov-15 IMMUNE DESIGN CORP. Files SEC form 8-K, Change in Directors or Principal Officers 12-Aug-15 IMMUNE DESIGN CORP. Files ...
01/11/16 03:50 PMImmune Design's Immunotherapy Drugs Get Orphan Status -
01/08/16 03:31 PMIMMUNE DESIGN CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
01/08/16 03:06 PMImmune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305 - [at noodls] - SEATTLE and SOUTH SAN FRANCISCO, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that the U.S. Food and ...
01/06/16 02:01 PMCommit To Buy Immune Design Corp At $12.50, Earn 26% Annualized Using Options - Investors considering a purchase of Immune Design Corp (IMDZ) stock, but tentative about paying the going market price of $17.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put ...
01/06/16 07:08 AMImmune Design Corp. breached its 50 day moving average in a Bearish Manner : January 6, 2016 -
12/30/15 03:24 PMIMMUNE DESIGN CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement -
12/21/15 11:55 AMImmune Design Corp. Earnings Analysis: Q3, 2015 By the Numbers -
12/08/15 12:17 PMIMMUNE DESIGN CORP. Financials -
12/07/15 04:03 PMImmune Design Highlights G100 Preclinical Data Demonstrating Direct and Abscopal Tumor Regression, Long-Term Response and Synergy With Checkpoint Blockade - [at noodls] - SEATTLE and SOUTH SAN FRANCISCO, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced the presentation of data ...
11/18/15 09:32 AMCan The Uptrend Continue for Immune Design (IMDZ)? -
11/13/15 09:35 AMImmune Design Posts Narrower-Than-Expected Loss for Q3 -
11/12/15 04:10 PMImmune Design stock drops after $7.4 million loss -

Social

About Immune Design Corp.

Immune Design Corp. logoImmune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body's immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms, ZVex and GLAAS, which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action. The Company's primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and, it believes, address the shortcomings of existing therapies. The Company's immuno-oncology product candidates are being developed in two separate approaches. The Specific Antigen approach uses selected antigens that are also present in the patient's tumor. The Endogenous Antigen approach relies on endogenous tumor antigens released during tumor lysis by treatments, such as chemotherapy or local radiation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IMDZ
  • CUSIP:
Key Metrics:
  • Previous Close: $7.16
  • 50 Day Moving Average: $8.82
  • 200 Day Moving Average: $11.48
  • P/E Ratio: N/A
  • P/E Growth: -0.55
  • Market Cap: $144.30M
  • Beta: 2.83
  • Current Year EPS Consensus Estimate: $-2.7 EPS
  • Next Year EPS Consensus Estimate: $-3.05 EPS
Additional Links:
Immune Design Corp. (NASDAQ:IMDZ) Chart for Monday, July, 25, 2016